Option Care Health (OPCH) 10-Q 4 Nov 21 2021 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2021	Nov. 02, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-11993
Entity Registrant Name	OPTION CARE HEALTH, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	05-0489664
Entity Address, Address Line One	3000 Lakeside Dr.
Entity Address, Address Line Two	Suite 300N,
Entity Address, City or Town	Bannockburn,
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60015
City Area Code	312
Local Phone Number	940-2443
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	OPCH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		179,875,193
Entity Central Index Key	0001014739
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 200,856	$ 99,265
Accounts receivable, net	355,650	328,340
Inventories	189,830	158,601
Prepaid expenses and other current assets	64,848	70,806
Total current assets	811,184	657,012
NONCURRENT ASSETS:
Property and equipment, net	106,788	121,149
Operating lease right-of-use asset	71,992	68,795
Intangible assets, net	343,764	351,052
Goodwill	1,428,610	1,428,610
Other noncurrent assets	23,806	20,821
Total noncurrent assets	1,974,960	1,990,427
TOTAL ASSETS	2,786,144	2,647,439
CURRENT LIABILITIES:
Accounts payable	318,561	282,913
Accrued compensation and employee benefits	64,676	58,899
Accrued expenses and other current liabilities	71,759	64,075
Current portion of operating lease liability	18,893	18,886
Current portion of long-term debt	11,775	9,250
Total current liabilities	485,664	434,023
NONCURRENT LIABILITIES:
Long-term debt, net of discount, deferred financing costs and current portion	1,117,823	1,115,103
Operating lease liability, net of current portion	71,684	70,776
Deferred income taxes	4,519	3,339
Other noncurrent liabilities	8,974	8,474
Total noncurrent liabilities	1,203,000	1,197,692
Total liabilities	1,688,664	1,631,715
STOCKHOLDERS’ EQUITY:
Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of September 30, 2021 and December 31, 2020, respectively	0	0
Common stock; $0.0001 par value: 250,000,000 shares authorized, 180,258,555 shares issued and 179,874,833 shares outstanding as of September 30, 2021; 180,178,308 shares issued and 179,794,586 shares outstanding as of December 31, 2020	18	18
Treasury stock; 383,722 shares outstanding, at cost, as of September 30, 2021 and December 31, 2020, respectively	(2,403)	(2,403)
Paid-in capital	1,135,465	1,129,312
Accumulated deficit	(35,600)	(100,031)
Accumulated other comprehensive loss	0	(11,172)
Total stockholders’ equity	1,097,480	1,015,724
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 2,786,144	$ 2,647,439

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	12,500,000	12,500,000
Preferred stock, shares, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares, issued (in shares)	180,258,555	180,178,308
Common stock, shares, outstanding (in shares)	179,874,833	179,794,586
Treasury stock, at cost (in shares)	383,722	383,722

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
NET REVENUE	$ 891,937	$ 781,609	$ 2,511,446	$ 2,227,897
COST OF REVENUE	688,969	607,456	1,944,037	1,729,395
GROSS PROFIT	202,968	174,153	567,409	498,502
OPERATING COSTS AND EXPENSES:
Selling, general and administrative expenses	134,633	123,000	388,930	377,198
Depreciation and amortization expense	15,452	16,597	48,410	54,892
Total operating expenses	150,085	139,597	437,340	432,090
OPERATING INCOME	52,883	34,556	130,069	66,412
OTHER INCOME (EXPENSE):
Interest expense, net	(16,000)	(24,583)	(52,717)	(84,102)
Equity in earnings of joint ventures	1,676	790	4,567	2,364
Other, net	4	(8,344)	(12,392)	(8,322)
Total other expense	(14,320)	(32,137)	(60,542)	(90,060)
INCOME (LOSS) BEFORE INCOME TAXES	38,563	2,419	69,527	(23,648)
INCOME TAX EXPENSE	3,087	756	5,096	2,267
NET INCOME (LOSS)	35,476	1,663	64,431	(25,915)
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:
Change in unrealized gains (losses) on cash flow hedges, net of income tax expense (benefit) of $0, $0, $0 and $0, respectively	2,892	4,022	11,172	(8,034)
OTHER COMPREHENSIVE INCOME (LOSS)	2,892	4,022	11,172	(8,034)
NET COMPREHENSIVE INCOME (LOSS)	$ 38,368	$ 5,685	$ 75,603	$ (33,949)
EARNINGS (LOSS) PER COMMON SHARE:
Earnings (loss) per share, basic (in dollars per share)	$ 0.20	$ 0.01	$ 0.36	$ (0.14)
Earnings (loss) per share, diluted (in dollars per share)	$ 0.20	$ 0.01	$ 0.36	$ (0.14)
Weighted average common shares outstanding, basic (in shares)	179,872	184,232	179,841	179,220
Weighted average common shares outstanding, diluted (in shares)	181,430	184,822	181,055	179,220

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Unrealized gains (losses) on cash flow hedges, net of income tax expense (benefit)	$ 0	$ 0	$ 0	$ 0

UNAUDITED CONDENSED CONSOLIDA_3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 64,431	$ (25,915)
Adjustments to reconcile net income (loss) to net cash provided by operations:
Depreciation and amortization expense	52,820	60,054
Non-cash operating lease costs	11,137	13,020
Paid-in-kind interest capitalized as principal	0	7,525
Deferred income taxes - net	1,180	897
Loss on extinguishment of debt	12,403	8,349
Amortization of deferred financing costs	3,821	4,153
Loss on interest rate swaps upon discontinuing hedge accounting	0	3,746
Equity in earnings of joint ventures	(4,567)	(2,364)
Stock-based incentive compensation expense	6,246	2,588
Other adjustments	2,622	1,589
Changes in operating assets and liabilities:
Accounts receivable, net	(27,310)	3,496
Inventories	(31,472)	(39,602)
Prepaid expenses and other current assets	5,958	(8,724)
Accounts payable	35,648	66,508
Accrued compensation and employee benefits	5,777	5,461
Accrued expenses and other current liabilities	18,353	16,768
Operating lease liabilities	(14,620)	(11,976)
Other noncurrent assets and liabilities	832	(3,845)
Net cash provided by operating activities	143,259	101,728
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment	(11,744)	(12,871)
Other investing cash flows	0	541
Business acquisitions, net of cash acquired	(18,852)	0
Net cash used in investing activities	(30,596)	(12,330)
CASH FLOWS FROM FINANCING ACTIVITIES:
Exercise of stock options, vesting of restricted stock, and related tax withholdings	(93)	(904)
Proceeds from issuance of debt	355,200	0
Repayments of debt	(8,832)	(6,937)
Retirement of debt	(352,009)	(125,000)
Deferred financing costs	(2,880)	0
Net proceeds from issuance of common stock	0	118,934
Debt prepayment fees	(2,458)	0
Other financing cash flows	0	(2,500)
Net cash (used in) provided by financing activities	(11,072)	(16,407)
NET INCREASE IN CASH AND CASH EQUIVALENTS	101,591	72,991
Cash and cash equivalents - beginning of the period	99,265	67,056
CASH AND CASH EQUIVALENTS - END OF PERIOD	200,856	140,047
Supplemental disclosure of cash flow information:
Cash paid for interest	52,002	73,224
Cash paid for income taxes	2,719	2,373
Cash paid for operating leases	$ 19,631	$ 19,941

UNAUDITED CONDENSED CONSOLIDA_4

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Treasury Stock	Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income
Equity, beginning balance at Dec. 31, 2019	$ 906,827	$ 0	$ 18	$ (2,403)	$ 1,008,362	$ (91,955)	$ (7,195)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options, vesting of restricted stock and related tax withholdings	(549)				(549)
Stock-based incentive compensation	757				757
Net income (loss)	(19,910)					(19,910)
Other comprehensive income (loss)	(16,632)						(16,632)
Equity, ending balance at Mar. 31, 2020	870,493	0	18	(2,403)	1,008,570	(111,865)	(23,827)
Equity, beginning balance at Dec. 31, 2019	906,827	0	18	(2,403)	1,008,362	(91,955)	(7,195)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(25,915)
Other comprehensive income (loss)	(8,034)
Equity, ending balance at Sep. 30, 2020	993,496	0	19	(2,403)	1,128,979	(117,870)	(15,229)
Equity, beginning balance at Mar. 31, 2020	870,493	0	18	(2,403)	1,008,570	(111,865)	(23,827)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options, vesting of restricted stock and related tax withholdings	(96)				(96)
Stock-based incentive compensation	661				661
Net income (loss)	(7,668)					(7,668)
Other comprehensive income (loss)	4,576						4,576
Equity, ending balance at Jun. 30, 2020	867,966	0	18	(2,403)	1,009,135	(119,533)	(19,251)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options, vesting of restricted stock and related tax withholdings	(259)				(259)
Stock-based incentive compensation	1,170				1,170
Net proceeds from the issuance of common stock	118,934		1		118,933
Net income (loss)	1,663					1,663
Other comprehensive income (loss)	4,022						4,022
Equity, ending balance at Sep. 30, 2020	993,496	0	19	(2,403)	1,128,979	(117,870)	(15,229)
Equity, beginning balance at Dec. 31, 2020	1,015,724	0	18	(2,403)	1,129,312	(100,031)	(11,172)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options, vesting of restricted stock and related tax withholdings	(69)				(69)
Stock-based incentive compensation	1,205				1,205
Net income (loss)	(2,861)					(2,861)
Other comprehensive income (loss)	4,081						4,081
Equity, ending balance at Mar. 31, 2021	1,018,080	0	18	(2,403)	1,130,448	(102,892)	(7,091)
Equity, beginning balance at Dec. 31, 2020	1,015,724	0	18	(2,403)	1,129,312	(100,031)	(11,172)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	64,431
Other comprehensive income (loss)	11,172
Equity, ending balance at Sep. 30, 2021	1,097,480	0	18	(2,403)	1,135,465	(35,600)	0
Equity, beginning balance at Mar. 31, 2021	1,018,080	0	18	(2,403)	1,130,448	(102,892)	(7,091)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options, vesting of restricted stock and related tax withholdings	(9)				(9)
Stock-based incentive compensation	2,525				2,525
Net income (loss)	31,816					31,816
Other comprehensive income (loss)	4,199						4,199
Equity, ending balance at Jun. 30, 2021	1,056,611	0	18	(2,403)	1,132,964	(71,076)	(2,892)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options, vesting of restricted stock and related tax withholdings	(15)				(15)
Stock-based incentive compensation	2,516				2,516
Net income (loss)	35,476					35,476
Other comprehensive income (loss)	2,892						2,892
Equity, ending balance at Sep. 30, 2021	$ 1,097,480	$ 0	$ 18	$ (2,403)	$ 1,135,465	$ (35,600)	$ 0

NATURE OF OPERATIONS AND PRESEN

NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Presentation of Financial Statements	NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS Corporate Organization and Business — HC Group Holdings II, Inc. (“HC II”) was incorporated under the laws of the State of Delaware on January 7, 2015, with its sole shareholder being HC Group Holdings I, LLC. (“HC I”). On April 7, 2015, HC I and HC II collectively acquired Walgreens Infusion Services, Inc. and its subsidiaries from Walgreen Co., and the business was rebranded as Option Care (“Option Care”). On March 14, 2019, HC I and HC II entered into a definitive agreement (the “Merger Agreement”) to merge with and into a wholly-owned subsidiary of BioScrip, Inc. (“BioScrip”), a national provider of infusion and home care management solutions, along with certain other subsidiaries of BioScrip and HC II. The merger contemplated by the Merger Agreement (the “Merger”) was completed on August 6, 2019 (the “Merger Date”). The Merger was accounted for as a reverse merger under the acquisition method of accounting for business combinations with Option Care being considered the accounting acquirer and BioScrip being considered the legal acquirer. Following the close of the transaction, BioScrip was rebranded as Option Care Health, Inc. (“Option Care Health”, or the “Company”). The combined Company’s stock is listed on the Nasdaq Global Select Market as of September 30, 2021. See Note 15, Stockholders’ Equity , for further discussion of HC I’s ownership as of September 30, 2021. Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary health care services through a national network of 98 full service pharmacies. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. The Company operates in one segment, infusion services. Basis of Presentation — The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2020 audited consolidated financial statements, including the notes thereto, as presented in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2021. Principles of Consolidation — The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation. The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company’s share of earnings from equity-method investments is included in the line entitled “Equity in earnings of joint ventures” in the unaudited condensed consolidated statements of comprehensive income (loss). See Equity-Method Investments within Note 2, Summary of Significant Accounting Policies , for further discussion of the Company’s equity-method investments.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. In April 2020, the Company received $11.7 million in Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) grant funds from the federal government, which was reflected in the second quarter 2020 as a cash inflow from financing activities within other financing cash flows in the unaudited condensed consolidated statements of cash flows. During the third quarter 2020, the Company returned the funds as unused to the federal government, which was reflected as a cash outflow from financing activities within other financing cash flows in the unaudited condensed consolidated statements of cash flows. Prepaid expenses and other current assets — Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $36.9 million and $35.2 million as of September 30, 2021 and December 31, 2020, respectively. There were no other items included in prepaid expenses and other current assets that comprised 5% or more of total current assets. Equity Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of September 30, 2021 and December 31, 2020, the balance of the investments were $20.3 million and $17.0 million, respectively. The investments are increased to reflect the Company’s capital contributions and equity in earnings of the investees. The investments are decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees are recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income (loss). The Company’s proportionate share of earnings was $1.7 million and $4.6 million for the three and nine months ended September 30, 2021. The Company’s proportionate share of earnings was $0.8 million and $2.4 million for the three and nine months ended September 30, 2020. Distributions from the investees are treated as cash inflows from operating activities within other adjustments in the unaudited condensed consolidated statements of cash flows. During the three and nine months ended September 30, 2021, the Company received distributions from the investees of $1.3 million and $1.3 million, respectively. During the three and nine months ended September 30, 2020, the Company received distributions from the investees of $2.3 million and $2.8 million, respectively. See Footnote 16, Related-Party Transactions , for discussion of related-party transactions with these investees. Immaterial Error Correction — During the three months ended June 30, 2021, the Company identified prior period misstatements related to the net revenue earned by category of payer for the periods ended September 30, 2020, December 31, 2020, March 31, 2021, and June 30, 2021. Certain individual payers were improperly classified as direct government and instead should have been classified as commercial payers. This error over-stated the Company’s government revenues and under-stated the Company’s commercial revenues in those periods. The Company assessed the materiality of these misstatements both quantitatively and qualitatively and determined the correction of these errors to be immaterial to the prior consolidated financial statements taken as a whole. As a result, the Company has corrected the misstatements as disclosed in the following tables: Three Months ended September 30, 2020 Nine Months ended September 30, 2020 Three Months ended December 31, 2020 Twelve Months ended December 31, 2020 Amount % of Revenue Amount % of Revenue Amount % of Revenue Amount % of Revenue Commercial: As Previously $ 644,385 82.4 % $ 1,893,105 85.0 % $ 649,880 80.8 % $ 2,542,985 83.9 % Adjustment 34,321 4.4 % 34,321 1.5 % 40,806 5.1 % 75,127 2.5 % As Revised 678,706 86.8 % 1,927,426 86.5 % 690,686 85.9 % 2,618,112 86.4 % Government: As Previously Reported 127,435 16.3 % 308,830 13.9 % 141,237 17.6 % 450,067 14.8 % Adjustment (34,321) (4.4) % (34,321) (1.5) % (40,806) (5.1) % (75,127) (2.5) % As Revised 93,114 11.9 % 274,509 12.4 % 100,431 12.5 % 374,940 12.3 % Three Months ended March 31, 2021 Three Months ended June 30, 2021 Six Months ended June 30, 2021 Amount % of Revenue Amount % of Revenue Amount % of Revenue Commercial: As Previously Reported $ 611,434 80.5 % $ 703,429 81.8 % $ 1,314,862 81.2 % Adjustment 37,073 4.9 % 43,218 5.0 % 80,292 4.9 % As Revised 648,507 85.4 % 746,647 86.8 % 1,395,154 86.1 % Government: As Previously Reported 134,914 17.8 % 145,799 16.9 % 280,714 17.3 % Adjustment (37,073) (4.9) % (43,218) (5.0) % (80,292) (4.9) % As Revised 97,841 12.9 % 102,581 11.9 % 200,422 12.4 % There was no impact to the Company’s consolidated balance sheets, consolidated statements of comprehensive income (loss) or the consolidated statements of cash flows for any of these periods. Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 16% and 16% for the three and nine months ended September 30, 2021. Revenue related to the Company’s largest payer was approxima tely 16% and 15% for the three and nine months ended September 30, 2020, respectively. In December 2019, the Company renewed and expanded its multi-year contract with this payer. The contract renewal was effective in February 2020 for a two-year term and auto-renews annually thereafter unless notice is provided. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented. For the three and nine months ended September 30, 2021, approximately 12% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. For the three and nine months ended September 30, 2020, approximately 12% and 12%, respectively, of the Company’s revenue was reimbursable through direct government health care programs, such as Medicare and Medicaid. As of September 30, 2021 and December 31, 2020, respectively, approximately 11% and 15%, respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term. The Company does not require its patients nor other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care, however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria. For the three and nine months ended September 30, 2021, approximately 65% and 65%, respectively, of the Company’s pharmaceutical and medical supply purchases were from three vendors. For the three and nine months ended September 30, 2020, approximately 71% and 72%, respectively, of the Company’s pharmaceutical and medical supply purchases were from three vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company’s financial condition or operating results. Although there remains some uncertainty regarding the COVID-19 pandemic, as of September 30, 2021 the Company has been able to maintain adequate levels of supplies and pharmaceuticals to support its operations.

BUSINESS COMBINATIONS AND ASSET

BUSINESS COMBINATIONS AND ASSET ACQUISITIONS	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Business Combinations and Asset Acquisitions	BUSINESS COMBINATIONS AND ASSET ACQUISITIONS BioCure Asset Acquisition — In April 2021, pursuant to the Asset Purchase Agreement dated April 7, 2021, the Company completed the acquisition of certain assets of BioCure, LLC (“BioCure”) for a purchase price of $18.9 million. The allocation of the purchase price of BioCure was accounted for as an asset acquisition in accordance with ASC Topic 805, Business Combinations , with the total purchase price being allocated to the assets acquired based on the relative fair value of each asset. The purchase price was allocated to the assets acquired as follows: Amount Inventories $ 601 Intangible assets, net 18,251 Total consideration transferred $ 18,852 Intangibles assets, net consists of referral sources which were assigned a useful life of 15 years, amortized on a straight-line basis.
Business Combinations and Asset Acquisitions	BUSINESS COMBINATIONS AND ASSET ACQUISITIONS BioCure Asset Acquisition — In April 2021, pursuant to the Asset Purchase Agreement dated April 7, 2021, the Company completed the acquisition of certain assets of BioCure, LLC (“BioCure”) for a purchase price of $18.9 million. The allocation of the purchase price of BioCure was accounted for as an asset acquisition in accordance with ASC Topic 805, Business Combinations , with the total purchase price being allocated to the assets acquired based on the relative fair value of each asset. The purchase price was allocated to the assets acquired as follows: Amount Inventories $ 601 Intangible assets, net 18,251 Total consideration transferred $ 18,852 Intangibles assets, net consists of referral sources which were assigned a useful life of 15 years, amortized on a straight-line basis.

REVENUE

REVENUE	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue	REVENUE The following table sets forth the net revenue earned by category of payer for the three and nine months ended September 30, 2021 and 2020 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Commercial payers $ 769,524 $ 678,706 $ 2,164,678 $ 1,927,426 Government payers 106,645 93,114 307,067 274,509 Patients 15,768 9,789 39,701 25,962 Net revenue $ 891,937 $ 781,609 $ 2,511,446 $ 2,227,897

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES During the three and nine months ended September 30, 2021, the Company recorded tax expense of $3.1 million and $5.1 million, respectively, which represents an effective tax rate of 8.0% and 7.3%, respectively. During the three and nine months ended September 30, 2020 the Company recorded a tax expense of $0.8 million and $2.3 million, respectively, which represents an effective tax rate of 31.3% and (9.6)%, respectively . The Company maintains a full valuation allowance of $97.3 million against all of its net U.S. federal and state deferred tax assets with the exception of $0.3 million of estimated state net operating losses (“NOL”). In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. The Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income and tax-planning strategies, in making this assessment. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated. Based on the Company’s full valuation allowance, as noted above, the Company’s tax expense for the three and nine months ended September 30, 2021 of $3.1 million and $5.1 million consists of quarterly tax liabilities attributable to specific state taxing authorities as well as recognized deferred tax expense. The Company has accumulated U.S. federal net operating loss carryovers that are subject to one or more Section 382 limitations. This may limit the Company’s ability to utilize its U.S. federal net operating losses. The Company recorded no income tax expense or benefit for the three or nine months ended September 30, 2021 and 2020 associated with the tax provisions of the CARES Act.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	EARNINGS (LOSS) PER SHARE The Company presents basic and diluted earnings (loss) per share for its common stock. Basic earnings (loss) per share is calculated by dividing the net income (loss) of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities. The earnings (loss) is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the three and nine months ended September 30, 2021 includes the effect of shares that would be issued in connection with warrants, stock options and restricted stock awards, as these common stock equivalents are dilutive to the earnings per share recorded in those periods. The computation of diluted shares for the nine months ended September 30, 2020 excludes the effect of these common stock equivalents as their inclusion would be anti-dilutive to the loss per share recorded in the period. For the three months ended September 30, 2021 there were 457,754 warrants, 496,929 stock option awards, and 38,536 restricted stock awards outstanding that were excluded from the calculation of earnings per share as they would be anti-dilutive. For the nine months ended September 30, 2021 there were 915,507 warrants, 387,656 stock option awards, and 272,540 restricted stock awards outstanding that were excluded from the calculation of earnings per share as they would be anti-dilutive. For the three months ended September 30, 2020, there were 915,507 warrants, 296,876 stock options and 312,984 restricted stock awards outstanding that were excluded from the calculation of earnings per share as they would be anti-dilutive. Fo r the nine months ended September 30, 2020, there were 2,328,120 warrants, 424,878 stock options and 600,483 restricted stock awards outstanding that were excluded from the calculation of loss per share as they would be anti-dilutive. The following table presents the Company’s basic earnings (loss) per share and shares outstanding (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net income (loss) $ 35,476 $ 1,663 $ 64,431 $ (25,915) Denominator: Weighted average number of common shares outstanding 179,872 184,232 179,841 179,220 Earnings (loss) per common share: Earnings (loss) per common share, basic $ 0.20 $ 0.01 $ 0.36 $ (0.14) The following table presents the Company’s diluted earnings (loss) per share and shares outstanding (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net income (loss) $ 35,476 $ 1,663 $ 64,431 $ (25,915) Denominator: Weighted average number of common shares outstanding 179,872 184,232 179,841 179,220 Effect of dilutive securities 1,558 590 1,214 — Weighted average number of common shares outstanding, diluted 181,430 184,822 181,055 179,220 Earnings (loss) per common share: Earnings (loss) per common share, diluted $ 0.20 $ 0.01 $ 0.36 $ (0.14)

LEASES

LEASES	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Leases	LEASES During the three and nine months ended September 30, 2021, the Company incurred operating lease expenses of $7.8 million and $22.3 million, respectively, including short-term lease expense, which were included as a component of selling, general and administrative expense in the unaudited condensed consolidated statements of comprehensive income (loss). During the three and nine months ended September 30, 2020, the Company incurred operating lease expense of $7.6 million and $23.0 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income (loss). As of September 30, 2021, the weighted-average remaining lease term was 6.44 and the weighted-average discount rate was 5.09%. Operating leases mature as follows (in thousands): Fiscal Year Ending December 31, Minimum Payments 2021 $ 8,379 2022 22,679 2023 19,324 2024 13,757 2025 11,053 Thereafter 32,682 Total lease payments $ 107,874 Less: Interest 17,297 Present value of lease liabilities $ 90,577 During the three and nine months ended September 30, 2021, the Company commenced new leases, extensions and amendments, resulting in non-cash investing and financing activities in the unaudited condensed consolidated statements of cash flow o f $14.5 million re lated to increases in the operating lease right-of-use asset and operating lease liabilities, respectively. During the three and nine months ended September 30, 2020, the Company commenced new leases, extensions and amendments, resulting in non-cash investing and financing activities in the unaudited condensed consolidated statements of cash flow of $20.1 million related to increases in the operating lease right-of-use asset and operating lease liabilities, respectively. As of September 30, 2021, the Company did not have any significant operating or financing leases that had not yet commenced.
Leases	LEASES During the three and nine months ended September 30, 2021, the Company incurred operating lease expenses of $7.8 million and $22.3 million, respectively, including short-term lease expense, which were included as a component of selling, general and administrative expense in the unaudited condensed consolidated statements of comprehensive income (loss). During the three and nine months ended September 30, 2020, the Company incurred operating lease expense of $7.6 million and $23.0 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the unaudited condensed consolidated statements of comprehensive income (loss). As of September 30, 2021, the weighted-average remaining lease term was 6.44 and the weighted-average discount rate was 5.09%. Operating leases mature as follows (in thousands): Fiscal Year Ending December 31, Minimum Payments 2021 $ 8,379 2022 22,679 2023 19,324 2024 13,757 2025 11,053 Thereafter 32,682 Total lease payments $ 107,874 Less: Interest 17,297 Present value of lease liabilities $ 90,577 During the three and nine months ended September 30, 2021, the Company commenced new leases, extensions and amendments, resulting in non-cash investing and financing activities in the unaudited condensed consolidated statements of cash flow o f $14.5 million re lated to increases in the operating lease right-of-use asset and operating lease liabilities, respectively. During the three and nine months ended September 30, 2020, the Company commenced new leases, extensions and amendments, resulting in non-cash investing and financing activities in the unaudited condensed consolidated statements of cash flow of $20.1 million related to increases in the operating lease right-of-use asset and operating lease liabilities, respectively. As of September 30, 2021, the Company did not have any significant operating or financing leases that had not yet commenced.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	PROPERTY AND EQUIPMENT Property and equipment was as follows as of September 30, 2021 and December 31, 2020 (in thousands): September 30, 2021 December 31, 2020 Infusion pumps $ 34,249 $ 31,678 Equipment, furniture and other 53,770 47,886 Leasehold improvements 91,789 87,483 Computer software, purchased and internally developed 29,804 27,799 Assets under development 7,894 10,793 217,506 205,639 Less: accumulated depreciation 110,718 84,490 Property and equipment, net $ 106,788 $ 121,149 Depreciation expense is recorded within cost of revenue and operating expenses within the unaudited condensed consolidated statements of comprehensive income (loss), depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the three and nine months ended September 30, 2021 and 2020 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Depreciation expense in cost of revenue $ 1,664 $ 1,643 $ 4,410 $ 5,161 Depreciation expense in operating expenses 7,476 7,814 22,670 28,546 Total depreciation expense $ 9,140 $ 9,457 $ 27,080 $ 33,707

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	GOODWILL AND OTHER INTANGIBLE ASSETS There was no change in the carrying amount of goodwill for the three or nine months ended September 30, 2021. Changes in the carrying amount of goodwill consists of the following activity for the three and nine months ended September 30, 2020 (in thousands): Balance at December 31, 2019 $ 1,425,542 Merger purchase accounting adjustments 2,341 Balance at March 31, 2020 $ 1,427,883 Merger purchase accounting adjustments 727 Balance at June 30, 2020 $ 1,428,610 Changes — Balance at September 30, 2020 $ 1,428,610 The carrying amount and accumulated amortization of intangible assets consists of the following as of September 30, 2021 and December 31, 2020 (in thousands): September 30, 2021 December 31, 2020 Gross intangible assets: Referral sources $ 456,372 $ 438,121 Trademarks/names 44,536 44,536 Other amortizable intangible assets 402 402 Total gross intangible assets 501,310 483,059 Accumulated amortization: Referral sources (130,758) (110,498) Trademarks/names (26,403) (21,146) Other amortizable intangible assets (385) (363) Total accumulated amortization (157,546) (132,007) Total intangible assets, net $ 343,764 $ 351,052 Amortization expense for intangible assets was $7.9 million and $25.5 million for the three and nine months ended September 30, 2021, respectively. Amortization expense for intangible assets was $8.8 million and $26.3 million for the three and nine months ended September 30, 2020, respectively.

INDEBTEDNESS

INDEBTEDNESS	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Indebtedness	INDEBTEDNESS Long-term debt consisted of the following as of September 30, 2021 (in thousands): Principal Amount Discount Debt Issuance Costs Net Balance Asset-based-lending (“ABL”) facility $ — $ — $ — $ — First lien term loan 1,156,919 (8,731) (18,590) 1,129,598 Second lien notes — — — — $ 1,156,919 $ (8,731) $ (18,590) 1,129,598 Less: current portion (11,775) Total long-term debt $ 1,117,823 Long-term debt consisted of the following as of December 31, 2020 (in thousands): Principal Amount Discount Debt Issuance Costs Net Balance ABL facility $ — $ — $ — $ — First lien term loan 915,750 (7,253) (19,710) 888,787 Second lien notes 245,781 (6,102) (4,113) 235,566 $ 1,161,531 $ (13,355) $ (23,823) 1,124,353 Less: current portion (9,250) Total long-term debt $ 1,115,103 In January 2021, the Company entered into an amendment on the First Lien Term Loan (the “First Lien Credit Agreement Amendment”). The First Lien Credit Agreement Amendment resulted in an additional $250.0 million of incremental First Lien Term Loan indebtedness being issued and reduced the interest rate on all outstanding First Lien Term Loan indebtedness from LIBOR plus 4.25% to LIBOR plus 3.75%. The proceeds of the $250.0 million incremental First Lien Term Loan indebtedness were used to prepay the remaining $245.8 million outstanding balance of the Second Lien Notes. Following the First Lien Credit Agreement Amendment, the First Lien Term Loan is repayable in quarterly installments of $2.9 million plus interest, with a final payment of all remaining outstanding principal due on August 6, 2026. The Company assessed whether the repayment of the Second Lien Notes by issuing incremental First Lien Term Loan indebtedness resulted in an insubstantial modification or an extinguishment of the existing debt for each loan in the syndication by grouping lenders as follows: (i) Lenders participating in both the First Lien Term Loan and Second Lien Notes; (ii) previous lenders that exited; and (iii) new lenders. The Company determined that $161.2 million of the First Lien Term Loan was extinguished and $122.9 million of the Second Lien Term Loan was extinguished, which is disclosed as an outflow from financing activities in the condensed consolidated statements of cash flows. The First Lien Term Loan and Second Lien Notes had insubstantial modifications for lenders that participated in both debt instruments, which resulted in a cash outflow from financing activities of $352.0 million in the condensed consolidated statements of cash flows. The Company determined that $356.2 million of new debt was issued related to the First Lien Term Loan, which is disclosed as an inflow from financing activities in the condensed consolidated statements of cash flows. In connection with the prepayment of the Second Lien Notes and incremental First Lien Term Loan indebtedness, the Company incurred $7.2 million in debt issuance costs and third-party fees, of which $3.7 million was capitalized, $0.9 million was expensed as a component of other expense and $2.6 million was expensed as a loss on extinguishment as a component of other expense in the condensed consolidated statements of comprehensive income (loss) for the nine months ended September 30, 2021. Further, $1.0 million of the total fees incurred of $7.2 million was netted against the $356.2 million of proceeds from debt as a component of the cash flows from financing activities, $2.9 million was presented as deferred financing costs as a component of cash flows from financing activities, $2.4 million was presented as debt prepayment fees as a component of cash flows from financing activities, and the remaining $0.9 million was included in cash flows from operating activities in the condensed consolidated statements of cash flows. The Company recognized a loss on extinguishment of debt of $12.4 million included in the line entitled “Other, net” in the unaudited condensed consolidated statements of comprehensive income (loss) for the nine months ended September 30, 2021, of which $2.6 million related to debt issue costs incurred with the incremental First Lien Term Loan indebtedness and prepayment of the Second Lien Notes, as discussed above, and $9.8 million related to existing deferred financing fees that were written off upon extinguishment. All remaining deferred financing fees that existed prior to the First Lien Credit Agreement Amendment were attributed to modified loans, and were capitalized and amortized over the remaining term of the First Lien Term Loan. The interest rate on the First Lien Term Loa n was 3.83% and 4.40% as of September 30, 2021 and December 31, 2020, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 3.84% and 5.87% for the three and nine months ended September 30, 2021. The weighted average interest rate incurred on the previous First Lien T erm Loan was 4.67% and 5.29% for the three and nine months ended September 30, 2020, respectively. The interest rate on the Second Lien Notes was 8.98% as of December 31, 2020. The weighted average interest rate incurred on the Second Lien Notes was 8.98% for the period January 1, 2021 through January 20, 2021, prior to the repayment of the outstanding balance. The weighted average interest rate incurred on the Second Lien Notes was 9.51% and 10.17% for the three and nine months ended September 30, 2020. Long-term debt matures as follows (in thousands): Year Ending December 31, Minimum Payments 2021 $ 2,944 2022 11,775 2023 11,775 2024 11,775 2025 11,775 Thereafter 1,106,875 Total $ 1,156,919 In October 2021, the Company entered into an amendment on the First Lien Term Loan, to provide $600 million of refinanced borrowings. In October 2021, the Company also issued $500 million in aggregate principal amount of senior notes. See Note 17, Subsequent Events , for further discussion. During the three and nine months ended September 30, 2021 and 2020, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 11, Derivative Instruments , for further discussion. The following table presents the estimated fair values of the Company’s debt obligations as of September 30, 2021 (in thousands): Financial Instrument Carrying Value as of September 30, 2021 Markets for Identical Item (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) First lien term loan $ 1,129,598 $ — $ 1,156,919 $ — Second lien notes — — — — Total debt instruments $ 1,129,598 $ — $ 1,156,919 $ — The following table sets forth the changes in Level 3 measurements for the three months ended March 31, 2021 (in thousands). As the Second Lien Notes were prepaid in Q1, there was no change in the fair value thereafter. Level 3 Measurements Second lien notes fair value as of January 1, 2021 $ 266,438 Principal prepayment (245,781) Change in fair value (20,657) Second lien notes fair value as of March 31, 2021 $ — See Note 12, Fair Value Measurements , for further discussion.

DERIVATIVE INSTRUMENTS

DERIVATIVE INSTRUMENTS	9 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	DERIVATIVE INSTRUMENTS The Company uses derivative financial instruments for hedging and non-trading purposes to limit the Company’s exposure to increases in interest rates related to its variable interest rate debt. Use of derivative financial instruments in hedging programs subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. In a hedging relationship, the change in the value of the derivative financial instrument is offset to a great extent by the change in the value of the underlying hedged item. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company’s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company’s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate. In August 2019, the Company entered into interest rate swap agreements that reduce the variability in the interest rates on the newly-issued debt obligations following the Merger with BioScrip. The first interest rate swap for $925.0 million notional was effective in August 2019 with $911.1 million designated as a cash flow hedge against the underlying interest rate on the first lien term loan interest payments indexed to one-month London Interbank Offered Rate (“LIBOR”) through August 2021. In accordance with ASU 2017-12, Targeted Improvements to Accounting for Hedges, the Company has determined that the $911.1 million designated cash flow hedge is perfectly effective. The remaining $13.9 million notional amount of the interest rate swap is not designated as a hedging instrument. The first interest rate swap expired in August 2021. The second interest rate swap of $400.0 million notional was effective in November 2019 and was designated as a cash flow hedge against the underlying interest rate on the second lien notes interest payments indexed to three-month LIBOR through November 2020. In May 2020, the Company elected to pay-in-kind (“PIK”) the second lien note’s quarterly interest payment due in August 2020. Upon making the PIK election, the Company determined that the hedged interest payment would no longer occur, resulting in an ineffective hedge, so the Company discontinued hedge accounting on its $400.0 million notional interest rate swap. As a result, the Company reclassified accumulated comprehensive loss of $3.7 million to interest expense, net in the unaudited condensed consolidated statements of comprehensive income (loss). The gains and losses associated with the $400.0 million notional swap were recognized in net income (loss) through interest expense until the swap expired in November 2020. The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands): Fair value - Derivatives in liability position Derivative Balance Sheet Caption September 30, 2021 December 31, 2020 Interest rate swaps designated as cash flow hedges Accrued expenses and other current liabilities $ — $ 11,172 Interest rate swaps not designated as cash flow hedges Accrued expenses and other current liabilities — 170 Total derivatives $ — $ 11,342 The gain and loss associated with the changes in the fair value of the effective portion of the hedging instrument are recorded into other comprehensive (loss) income. The gain and loss associated with the changes in the fair value of the $13.9 million notional amount not designated as a hedging instrument is recognized in net income (loss) through interest expense. The following table presents the pre-tax gains (losses) from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (loss) (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Derivative 2021 2020 2021 2020 Interest rate swaps designated as cash flow hedges $ 2,892 $ 4,022 $ 11,172 $ (11,780) Interest rate swaps that discontinued hedge accounting — — — 3,746 $ 2,892 $ 4,022 $ 11,172 $ (8,034) The following table presents the amount and location of pre-tax income (loss) recognized in the Company’s unaudited condensed consolidated statement of comprehensive income (loss) related to the Company’s derivative instruments (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Derivative Income Statement Caption 2021 2020 2021 2020 Interest rate swaps designated as cash flow hedges Interest expense $ (2,903) $ (4,152) $ (11,298) $ (8,604) Interest rate swaps not designated as hedges Interest expense — (41) (2) (32) Interest rate swaps that discontinued hedge accounting Interest expense — — — (3,746) $ (2,903) $ (4,193) $ (11,300) $ (12,382)

FAIR VALUE MEASURMENTS

FAIR VALUE MEASURMENTS	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows: • Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. • Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. First lien term loan : The fair value of the first lien term loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 10, Indebtedness , for further discussion of the carrying amount and fair value of the first lien term loan. Second lien notes : Prior to the January 2021 debt refinancing, the fair value of the second lien notes was derived from a cash flow model that discounted the cash flows based on market interest rates (Level 3 inputs). See Note 10, Indebtedness , for further discussion of the carrying amount and fair value of the second lien notes. Interest rate swaps : The fair values of interest rate swaps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 11, Derivative Instruments , for further discussion of the fair value of interest rate swaps. There were no other assets or liabilities measured at fair value at September 30, 2021 and December 31, 2020.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIESThe Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company’s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized. The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s condensed consolidated balance sheets. However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.

STOCK-BASED INCENTIVE COMPENSAT

STOCK-BASED INCENTIVE COMPENSATION	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Incentive Compensation	STOCK-BASED INCENTIVE COMPENSATION Equity Incentive Plans — Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by the BioScrip stockholders on May 3, 2018, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 plan is administered by the Company’s Compensation Committee, a standing committee of the Board of Directors. A total of 9,101,734 shares of common stock are authorized for issuance. The Company had stock options, restricted stock and performance stock units outstanding related to the 2018 Plan as of September 30, 2021. As of September 30, 2021, the Company also had incentive units outstanding related to the HC I equity incentive plan, which was implemented in October 2015, for certain officers and employees of the Company. During the three and nine months ended September 30, 2021, total stock-based incentive compensation expense recognized by the Company related to these plans was $2.5 million and $6.2 million, respectively. During the three and nine months ended September 30, 2020, total stock-based incentive compensation expense recognized by the Company related to these plans was $1.2 million and $2.6 million, respectively.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders' Equity	STOCKHOLDERS’ EQUITY During the three and nine months ended September 30, 2021, HC I completed secondary offerings of 29,900,000 and 76,400,000 shares of common stock, respectively. Following these offerings, HC I holds approximately 21.1% of the common stock of the Company. 2017 Warrants — During the three and nine months ended September 30, 2021, warrant holders did not elect to exercise any warrants to purchase shares of common stock. During the three and nine months ended September 30, 2020, warrant holders did not elect to exercise any warrants to purchase shares of common stock. As of September 30, 2021 and December 31, 2020, the remaining warrant holders are entitled to purchase 1.4 million shares of common stock, respectively. 2015 Warrants — During the three and nine months ended September 30, 2021, warrant holders did not elect to exercise any warrants to purchase shares of common stock. During the three and nine months ended September 30, 2020, warrant holders did not elect to exercise any warrants to purchase shares of common stock. As of September 30, 2021 and December 31, 2020, warrant holders are entitled to purchase 0.9 million shares of common stock, respectively.

RELATED-PARTY TRANSACTIONS

RELATED-PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related-Party Transactions	RELATED-PARTY TRANSACTIONS Transactions with Equity-Method Investees — The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $0.9 million and $2.6 million for the three and nine months ended September 30, 2021, respectively. The Company recorded management fee income of $0.8 million and $2.1 million for the three and nine months ended September 30, 2020, respectively. Management fees are recorded in net revenues in the accompanying unaudited condensed consolidated statements of comprehensive income (loss). The Company had amounts due to its joint ventures of $2.9 million as of September 30, 2021. This payable was included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheets. The Company also had amounts due from its joint ventures of $2.4 million as of December 31, 2020. These receivables were included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS The Company has evaluated whether any subsequent events occurred since September 30, 2021, and noted the following subsequent events: On October 1, 2021 the Company acquired Infinity Infusion Nursing, LLC (“Infinity”) for $50 million in an all-cash transaction. Infinity is a leader in home infusion services that provide therapy management for patients with acute, chronic and rare disorders through a national network of highly-skilled, specialty nurses. In October 2021, the Company refinanced its $1,157 million outstanding existing loan due 2026. The Company amended the existing First Lien Term Loan, to provide $600 million of refinanced borrowings (the “New First Lien Term Loan Facility”) which modified certain terms and extended its maturity to 2028. In conjunction with the refinancing, the Company also issued $500 million in aggregate principal of unsecured senior notes due 2029 (collectively, the “Transactions”). In connection with

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation — The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States and contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for interim financial reporting. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire year. These unaudited condensed consolidated financial statements do not include all of the information and notes to the financial statements required by GAAP for complete financial statements and should be read in conjunction with the 2020 audited consolidated financial statements, including the notes thereto, as presented in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2021.
Principles of Consolidation	Principles of Consolidation — The Company’s unaudited condensed consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.
Cash and Cash Equivalents	Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.
Equity Method Investments	Equity Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying condensed consolidated balance sheets. As of September 30, 2021 and December 31, 2020, the balance of the investments were $20.3 million and $17.0 million, respectively. The investments are increased to reflect the Company’s capital contributions and equity in earnings of the investees. The investments are decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees are recorded in equity in earnings of joint ventures in the accompanying unaudited condensed consolidated statements of comprehensive income (loss).
Concentrations of Business Risk	Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 16% and 16% for the three and nine months ended September 30, 2021. Revenue related to the Company’s largest payer was approxima tely 16% and 15% for the three and nine months ended September 30, 2020, respectively. In December 2019, the Company renewed and expanded its multi-year contract with this payer. The contract renewal was effective in February 2020 for a two-year term and auto-renews annually thereafter unless notice is provided. There were no other managed care contracts that represent greater than 10% of revenue for the periods presented. For the three and nine months ended September 30, 2021, approximately 12% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid. For the three and nine months ended September 30, 2020, approximately 12% and 12%, respectively, of the Company’s revenue was reimbursable through direct government health care programs, such as Medicare and Medicaid. As of September 30, 2021 and December 31, 2020, respectively, approximately 11% and 15%, respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term. The Company does not require its patients nor other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentration of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care, however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.
Fair Value Measurements	FAIR VALUE MEASUREMENTS Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The categories within the valuation hierarchy are described as follows: • Level 1 — Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. • Level 3 — Inputs to the fair value measurement are unobservable inputs or valuation techniques. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. First lien term loan : The fair value of the first lien term loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 10, Indebtedness , for further discussion of the carrying amount and fair value of the first lien term loan. Second lien notes : Prior to the January 2021 debt refinancing, the fair value of the second lien notes was derived from a cash flow model that discounted the cash flows based on market interest rates (Level 3 inputs). See Note 10, Indebtedness , for further discussion of the carrying amount and fair value of the second lien notes. Interest rate swaps : The fair values of interest rate swaps are derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 11, Derivative Instruments , for further discussion of the fair value of interest rate swaps.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	As a result, the Company has corrected the misstatements as disclosed in the following tables: Three Months ended September 30, 2020 Nine Months ended September 30, 2020 Three Months ended December 31, 2020 Twelve Months ended December 31, 2020 Amount % of Revenue Amount % of Revenue Amount % of Revenue Amount % of Revenue Commercial: As Previously $ 644,385 82.4 % $ 1,893,105 85.0 % $ 649,880 80.8 % $ 2,542,985 83.9 % Adjustment 34,321 4.4 % 34,321 1.5 % 40,806 5.1 % 75,127 2.5 % As Revised 678,706 86.8 % 1,927,426 86.5 % 690,686 85.9 % 2,618,112 86.4 % Government: As Previously Reported 127,435 16.3 % 308,830 13.9 % 141,237 17.6 % 450,067 14.8 % Adjustment (34,321) (4.4) % (34,321) (1.5) % (40,806) (5.1) % (75,127) (2.5) % As Revised 93,114 11.9 % 274,509 12.4 % 100,431 12.5 % 374,940 12.3 % Three Months ended March 31, 2021 Three Months ended June 30, 2021 Six Months ended June 30, 2021 Amount % of Revenue Amount % of Revenue Amount % of Revenue Commercial: As Previously Reported $ 611,434 80.5 % $ 703,429 81.8 % $ 1,314,862 81.2 % Adjustment 37,073 4.9 % 43,218 5.0 % 80,292 4.9 % As Revised 648,507 85.4 % 746,647 86.8 % 1,395,154 86.1 % Government: As Previously Reported 134,914 17.8 % 145,799 16.9 % 280,714 17.3 % Adjustment (37,073) (4.9) % (43,218) (5.0) % (80,292) (4.9) % As Revised 97,841 12.9 % 102,581 11.9 % 200,422 12.4 %

BUSINESS COMBINATIONS AND ASS_2

BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables)	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of Acquired Identifiable Assets and Assumed Liabilities	The purchase price was allocated to the assets acquired as follows: Amount Inventories $ 601 Intangible assets, net 18,251 Total consideration transferred $ 18,852

REVENUE (Tables)

REVENUE (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Schedule of Net Revenue Earned by Category of Payer	The following table sets forth the net revenue earned by category of payer for the three and nine months ended September 30, 2021 and 2020 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Commercial payers $ 769,524 $ 678,706 $ 2,164,678 $ 1,927,426 Government payers 106,645 93,114 307,067 274,509 Patients 15,768 9,789 39,701 25,962 Net revenue $ 891,937 $ 781,609 $ 2,511,446 $ 2,227,897

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earnings (Loss) Per Share	The following table presents the Company’s basic earnings (loss) per share and shares outstanding (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net income (loss) $ 35,476 $ 1,663 $ 64,431 $ (25,915) Denominator: Weighted average number of common shares outstanding 179,872 184,232 179,841 179,220 Earnings (loss) per common share: Earnings (loss) per common share, basic $ 0.20 $ 0.01 $ 0.36 $ (0.14) The following table presents the Company’s diluted earnings (loss) per share and shares outstanding (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net income (loss) $ 35,476 $ 1,663 $ 64,431 $ (25,915) Denominator: Weighted average number of common shares outstanding 179,872 184,232 179,841 179,220 Effect of dilutive securities 1,558 590 1,214 — Weighted average number of common shares outstanding, diluted 181,430 184,822 181,055 179,220 Earnings (loss) per common share: Earnings (loss) per common share, diluted $ 0.20 $ 0.01 $ 0.36 $ (0.14)

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Maturities of Lease Liabilities, Operating	Operating leases mature as follows (in thousands): Fiscal Year Ending December 31, Minimum Payments 2021 $ 8,379 2022 22,679 2023 19,324 2024 13,757 2025 11,053 Thereafter 32,682 Total lease payments $ 107,874 Less: Interest 17,297 Present value of lease liabilities $ 90,577

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment was as follows as of September 30, 2021 and December 31, 2020 (in thousands): September 30, 2021 December 31, 2020 Infusion pumps $ 34,249 $ 31,678 Equipment, furniture and other 53,770 47,886 Leasehold improvements 91,789 87,483 Computer software, purchased and internally developed 29,804 27,799 Assets under development 7,894 10,793 217,506 205,639 Less: accumulated depreciation 110,718 84,490 Property and equipment, net $ 106,788 $ 121,149 Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Depreciation expense in cost of revenue $ 1,664 $ 1,643 $ 4,410 $ 5,161 Depreciation expense in operating expenses 7,476 7,814 22,670 28,546 Total depreciation expense $ 9,140 $ 9,457 $ 27,080 $ 33,707

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of the Carrying Amount of Goodwill	Changes in the carrying amount of goodwill consists of the following activity for the three and nine months ended September 30, 2020 (in thousands): Balance at December 31, 2019 $ 1,425,542 Merger purchase accounting adjustments 2,341 Balance at March 31, 2020 $ 1,427,883 Merger purchase accounting adjustments 727 Balance at June 30, 2020 $ 1,428,610 Changes — Balance at September 30, 2020 $ 1,428,610
Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets	The carrying amount and accumulated amortization of intangible assets consists of the following as of September 30, 2021 and December 31, 2020 (in thousands): September 30, 2021 December 31, 2020 Gross intangible assets: Referral sources $ 456,372 $ 438,121 Trademarks/names 44,536 44,536 Other amortizable intangible assets 402 402 Total gross intangible assets 501,310 483,059 Accumulated amortization: Referral sources (130,758) (110,498) Trademarks/names (26,403) (21,146) Other amortizable intangible assets (385) (363) Total accumulated amortization (157,546) (132,007) Total intangible assets, net $ 343,764 $ 351,052

INDEBTEDNESS (Tables)

INDEBTEDNESS (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Summary of Debt	Long-term debt consisted of the following as of September 30, 2021 (in thousands): Principal Amount Discount Debt Issuance Costs Net Balance Asset-based-lending (“ABL”) facility $ — $ — $ — $ — First lien term loan 1,156,919 (8,731) (18,590) 1,129,598 Second lien notes — — — — $ 1,156,919 $ (8,731) $ (18,590) 1,129,598 Less: current portion (11,775) Total long-term debt $ 1,117,823 Long-term debt consisted of the following as of December 31, 2020 (in thousands): Principal Amount Discount Debt Issuance Costs Net Balance ABL facility $ — $ — $ — $ — First lien term loan 915,750 (7,253) (19,710) 888,787 Second lien notes 245,781 (6,102) (4,113) 235,566 $ 1,161,531 $ (13,355) $ (23,823) 1,124,353 Less: current portion (9,250) Total long-term debt $ 1,115,103
Schedule of Long-term Debt Maturities	Long-term debt matures as follows (in thousands): Year Ending December 31, Minimum Payments 2021 $ 2,944 2022 11,775 2023 11,775 2024 11,775 2025 11,775 Thereafter 1,106,875 Total $ 1,156,919
Schedule of Estimated Fair Values of Debt Obligations	The following table presents the estimated fair values of the Company’s debt obligations as of September 30, 2021 (in thousands): Financial Instrument Carrying Value as of September 30, 2021 Markets for Identical Item (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) First lien term loan $ 1,129,598 $ — $ 1,156,919 $ — Second lien notes — — — — Total debt instruments $ 1,129,598 $ — $ 1,156,919 $ — The following table sets forth the changes in Level 3 measurements for the three months ended March 31, 2021 (in thousands). As the Second Lien Notes were prepaid in Q1, there was no change in the fair value thereafter. Level 3 Measurements Second lien notes fair value as of January 1, 2021 $ 266,438 Principal prepayment (245,781) Change in fair value (20,657) Second lien notes fair value as of March 31, 2021 $ —

DERIVATIVE INSTRUMENTS (Tables)

DERIVATIVE INSTRUMENTS (Tables)	9 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Amount and Location of Derivatives in the Balance Sheet	The following table summarizes the amount and location of the Company’s derivative instruments in the condensed consolidated balance sheets (in thousands): Fair value - Derivatives in liability position Derivative Balance Sheet Caption September 30, 2021 December 31, 2020 Interest rate swaps designated as cash flow hedges Accrued expenses and other current liabilities $ — $ 11,172 Interest rate swaps not designated as cash flow hedges Accrued expenses and other current liabilities — 170 Total derivatives $ — $ 11,342
Schedule of Pre-tax Gains (Losses) Recognized in the Statements of Comprehensive Income (Loss)	The following table presents the pre-tax gains (losses) from derivative instruments recognized in other comprehensive (loss) income in the Company’s unaudited condensed consolidated statements of comprehensive income (loss) (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Derivative 2021 2020 2021 2020 Interest rate swaps designated as cash flow hedges $ 2,892 $ 4,022 $ 11,172 $ (11,780) Interest rate swaps that discontinued hedge accounting — — — 3,746 $ 2,892 $ 4,022 $ 11,172 $ (8,034) The following table presents the amount and location of pre-tax income (loss) recognized in the Company’s unaudited condensed consolidated statement of comprehensive income (loss) related to the Company’s derivative instruments (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Derivative Income Statement Caption 2021 2020 2021 2020 Interest rate swaps designated as cash flow hedges Interest expense $ (2,903) $ (4,152) $ (11,298) $ (8,604) Interest rate swaps not designated as hedges Interest expense — (41) (2) (32) Interest rate swaps that discontinued hedge accounting Interest expense — — — (3,746) $ (2,903) $ (4,193) $ (11,300) $ (12,382)

NATURE OF OPERATIONS AND PRES_2

NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)	9 Months Ended
	Sep. 30, 2021pharmacy_locationsegment
Business Acquisition [Line Items]
Number of operating segments | segment	1
OptionCare Enterprises, Inc.
Business Acquisition [Line Items]
Number of service locations | pharmacy_location	98
Legacy Health Systems
Business Acquisition [Line Items]
Ownership interest	50.00%

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Feb. 29, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Apr. 30, 2020
Concentration Risk [Line Items]
CARES Act grant							$ 11,700
Rebate receivable		$ 36,900		$ 36,900		$ 35,200
Investments in equity-method investees		20,300		20,300		$ 17,000
Proportionate share of earnings in equity-method investees		1,700	$ 800	4,567	$ 2,364
Distributions received from the investees		$ 1,300	$ 2,300	$ 1,300	$ 2,800
Revenue from Contract with Customer Benchmark | Company's Largest Payer
Concentration Risk [Line Items]
Concentration ​risk		16.00%	16.00%	16.00%	15.00%
Contract term	2 years
Revenue from Contract with Customer Benchmark | Governmental Healthcare Programs
Concentration Risk [Line Items]
Concentration ​risk		12.00%	12.00%	12.00%	12.00%
Accounts Receivable | Governmental Healthcare Programs
Concentration Risk [Line Items]
Concentration ​risk				11.00%		15.00%
Cost of Goods and Service, Product and Service Benchmark | Medical Supply Vendors
Concentration Risk [Line Items]
Concentration ​risk		65.00%	71.00%	65.00%	72.00%

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Immaterial Error Correction (Details) - USD ($) $ in Thousands	3 Months Ended					6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Concentration Risk [Line Items]
Net revenue	$ 891,937				$ 781,609		$ 2,511,446	$ 2,227,897
Commercial:
Concentration Risk [Line Items]
Net revenue	769,524	$ 746,647	$ 648,507	$ 690,686	$ 678,706	$ 1,395,154	2,164,678	$ 1,927,426	$ 2,618,112
Commercial: | Revenue Benchmark | Company's Largest Payer
Concentration Risk [Line Items]
% of Revenue		86.80%	85.40%	85.90%	86.80%	86.10%		86.50%	86.40%
Government:
Concentration Risk [Line Items]
Net revenue	$ 106,645	$ 102,581	$ 97,841	$ 100,431	$ 93,114	$ 200,422	$ 307,067	$ 274,509	$ 374,940
Government: | Revenue Benchmark | Company's Largest Payer
Concentration Risk [Line Items]
% of Revenue		11.90%	12.90%	12.50%	11.90%	12.40%		12.40%	12.30%
As Previously Reported | Commercial:
Concentration Risk [Line Items]
Net revenue		$ 703,429	$ 611,434	$ 649,880	$ 644,385	$ 1,314,862		$ 1,893,105	$ 2,542,985
As Previously Reported | Commercial: | Revenue Benchmark | Company's Largest Payer
Concentration Risk [Line Items]
% of Revenue		81.80%	80.50%	80.80%	82.40%	81.20%		85.00%	83.90%
As Previously Reported | Government:
Concentration Risk [Line Items]
Net revenue		$ 145,799	$ 134,914	$ 141,237	$ 127,435	$ 280,714		$ 308,830	$ 450,067
As Previously Reported | Government: | Revenue Benchmark | Company's Largest Payer
Concentration Risk [Line Items]
% of Revenue		16.90%	17.80%	17.60%	16.30%	17.30%		13.90%	14.80%
Adjustment | Commercial:
Concentration Risk [Line Items]
Net revenue		$ 43,218	$ 37,073	$ 40,806	$ 34,321	$ 80,292		$ 34,321	$ 75,127
Adjustment | Commercial: | Revenue Benchmark | Company's Largest Payer
Concentration Risk [Line Items]
% of Revenue		5.00%	4.90%	5.10%	4.40%	4.90%		1.50%	2.50%
Adjustment | Government:
Concentration Risk [Line Items]
Net revenue		$ (43,218)	$ (37,073)	$ (40,806)	$ (34,321)	$ (80,292)		$ (34,321)	$ (75,127)
Adjustment | Government: | Revenue Benchmark | Company's Largest Payer
Concentration Risk [Line Items]
% of Revenue		(5.00%)	(4.90%)	(5.10%)	(4.40%)	(4.90%)		(1.50%)	(2.50%)

BUSINESS COMBINATIONS AND ASS_3

BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Additional Information (Details) - BioCure $ in Millions	Apr. 07, 2021USD ($)
Business Acquisition [Line Items]
Business combination purchase price	$ 18.9
Intangible assets useful life	15 years

BUSINESS COMBINATIONS AND ASS_4

BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Acquired Identifiable Assets and Assumed Liabilities (Details) - BioCure $ in Thousands	Apr. 07, 2021USD ($)
Business Acquisition [Line Items]
Inventories	$ 601
Intangible assets, net	18,251
Total consideration transferred	$ 18,852

REVENUE - Net Revenue Earned by

REVENUE - Net Revenue Earned by Category of Payer (Details) - USD ($) $ in Thousands	3 Months Ended					6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Net revenue	$ 891,937				$ 781,609		$ 2,511,446	$ 2,227,897
Commercial payers
Disaggregation of Revenue [Line Items]
Net revenue	769,524	$ 746,647	$ 648,507	$ 690,686	678,706	$ 1,395,154	2,164,678	1,927,426	$ 2,618,112
Government payers
Disaggregation of Revenue [Line Items]
Net revenue	106,645	$ 102,581	$ 97,841	$ 100,431	93,114	$ 200,422	307,067	274,509	$ 374,940
Patients
Disaggregation of Revenue [Line Items]
Net revenue	$ 15,768				$ 9,789		$ 39,701	$ 25,962

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income tax (benefit) expense	$ 3,087,000	$ 756,000	$ 5,096,000	$ 2,267,000
Effective tax rate	8.00%	31.30%	7.30%	(9.60%)
Valuation allowance	$ 97,300,000		$ 97,300,000
State net operating losses	300,000		300,000
Tax expense (benefit) for CARES Act	$ 0	$ 0	$ 0	$ 0

EARNINGS (LOSS) PER SHARE - Sch

EARNINGS (LOSS) PER SHARE - Schedule of Basic and Diluted Earnings (Loss) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Numerator:
Net income (loss)	$ 35,476	$ 31,816	$ (2,861)	$ 1,663	$ (7,668)	$ (19,910)	$ 64,431	$ (25,915)
Denominator:
Weighted average number of common shares outstanding (in shares)	179,872,000			184,232,000			179,841,000	179,220,000
Effect of dilutive securities (in shares)	1,558,000			590,000			1,214,000	0
Weighted average common shares outstanding, diluted (in shares)	181,430,000			184,822,000			181,055,000	179,220,000
Earnings (loss) per common share:
Earnings (loss) per share, basic (in dollars per share)	$ 0.20			$ 0.01			$ 0.36	$ (0.14)
Earnings (loss) per share, diluted (in dollars per share)	$ 0.20			$ 0.01			$ 0.36	$ (0.14)
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	457,754			915,507			915,507	2,328,120
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	496,929			296,876			387,656	424,878
Restricted Stock Award
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded (in shares)	38,536			312,984			272,540	600,483

LEASES - Additional Information

LEASES - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Operating lease cost	$ 7.8	$ 7.6	$ 22.3	$ 23
Weighted-average remaining lease term, operating leases	6 years 5 months 8 days		6 years 5 months 8 days
Weighted-average discount rate, operating leases	5.09%		5.09%
Increase in operating lease right-of-use asset and lease liabilities	$ 14.5	$ 20.1	$ 14.5	$ 20.1

LEASES - Maturities of Lease Li

LEASES - Maturities of Lease Liabilities (Details) $ in Thousands	Sep. 30, 2021USD ($)
Minimum Payments
2021	$ 8,379
2022	22,679
2023	19,324
2024	13,757
2025	11,053
Thereafter	32,682
Total lease payments	107,874
Less: Interest	17,297
Present value of lease liabilities	$ 90,577

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 217,506		$ 217,506		$ 205,639
Less: accumulated depreciation	110,718		110,718		84,490
Property and equipment, net	106,788		106,788		121,149
Total depreciation expense	9,140	$ 9,457	27,080	$ 33,707
Depreciation expense in cost of revenue
Property, Plant and Equipment [Line Items]
Total depreciation expense	1,664	1,643	4,410	5,161
Depreciation expense in operating expenses
Property, Plant and Equipment [Line Items]
Total depreciation expense	7,476	$ 7,814	22,670	$ 28,546
Infusion pumps
Property, Plant and Equipment [Line Items]
Property and equipment, gross	34,249		34,249		31,678
Equipment, furniture and other
Property, Plant and Equipment [Line Items]
Property and equipment, gross	53,770		53,770		47,886
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	91,789		91,789		87,483
Computer software, purchased and internally developed
Property, Plant and Equipment [Line Items]
Property and equipment, gross	29,804		29,804		27,799
Assets under development
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 7,894		$ 7,894		$ 10,793

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Change in the carrying amount	$ 0	$ 0	$ 727,000	$ 2,341,000	$ 0
Goodwill [Roll Forward]
Goodwill - net book value, begging of period		1,428,610,000	1,427,883,000	1,425,542,000	1,428,610,000
Merger purchase accounting adjustments and changes	0	0	727,000	2,341,000	0
Goodwill - net book value, end of period	$ 1,428,610,000	$ 1,428,610,000	$ 1,428,610,000	$ 1,427,883,000	$ 1,428,610,000

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	$ 501,310		$ 501,310		$ 483,059
Total accumulated amortization	(157,546)		(157,546)		(132,007)
Total intangible assets, net	343,764		343,764		351,052
Amortization expense for intangible assets	7,900	$ 8,800	25,500	$ 26,300
Referral sources
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	456,372		456,372		438,121
Total accumulated amortization	(130,758)		(130,758)		(110,498)
Trademarks/names
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	44,536		44,536		44,536
Total accumulated amortization	(26,403)		(26,403)		(21,146)
Other amortizable intangible assets
Finite-Lived Intangible Assets [Line Items]
Total gross intangible assets	402		402		402
Total accumulated amortization	$ (385)		$ (385)		$ (363)

INDEBTEDNESS - Summary of Debt

INDEBTEDNESS - Summary of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Principal Amount	$ 1,156,919	$ 1,161,531
Discount	(8,731)	(13,355)
Debt Issuance Costs	(18,590)	(23,823)
Net Balance	1,129,598	1,124,353
Less: current portion	(11,775)	(9,250)
Total long-term debt	1,117,823	1,115,103
Senior Notes | First lien term loan
Debt Instrument [Line Items]
Principal Amount	1,156,919	915,750
Discount	(8,731)	(7,253)
Debt Issuance Costs	(18,590)	(19,710)
Net Balance	1,129,598	888,787
Senior Notes | Second lien notes
Debt Instrument [Line Items]
Principal Amount	0	245,781
Discount	0	(6,102)
Debt Issuance Costs	0	(4,113)
Net Balance	0	235,566
Senior Notes | Asset-based-lending (“ABL”) facility
Debt Instrument [Line Items]
Principal Amount	0	0
Discount	0	0
Debt Issuance Costs	0	0
Net Balance	$ 0	$ 0

INDEBTEDNESS - Additional Infor

INDEBTEDNESS - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2021	Jan. 20, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Oct. 31, 2021
Debt Instrument [Line Items]
Repayment of debt					$ 8,832,000	$ 6,937,000
Cash outflow from financing activities					11,072,000	16,407,000
Proceeds from issuance of debt					355,200,000	0
Debt issuance costs			$ 18,590,000		18,590,000		$ 23,823,000
Loss on extinguishment of debt					12,403,000	8,349,000
Deferred financing costs					2,880,000	$ 0
Senior Notes
Debt Instrument [Line Items]
Loss on extinguishment of debt					12,400,000
Senior Notes | Subsequent Event
Debt Instrument [Line Items]
Legal fees								$ 9,400,000
Credit Agreements Amendment
Debt Instrument [Line Items]
Prepayment penalty			2,400,000		2,400,000
Credit Agreements Amendment | Senior Notes
Debt Instrument [Line Items]
Cash outflow from financing activities					352,000,000
Proceeds from issuance of debt					356,200,000
Legal fees			7,200,000		7,200,000
Debt issuance costs			3,700,000		3,700,000
Accumulated amortization expensed			$ 900,000		900,000
Loss on extinguishment of debt					9,800,000
Deferred financing costs					1,000,000
Payments of financing costs					2,900,000
Payments of debt issuance costs in operating activities					900,000
New Senior Unsecured Notes | Senior Notes | Subsequent Event
Debt Instrument [Line Items]
Debt instrument, face amount								500,000,000
First Lien Term Loan | Credit Agreements Amendment | Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount	$ 250,000,000
Debt instrument, basis spread	3.75%						4.25%
Repayment of debt					161,200,000
Debt principal payment					2,900,000
Loss on extinguishment of debt					$ 2,600,000
Effective rate on term loans at end of period			3.83%		3.83%		4.40%
Weighted average interest rate paid on term loans during period			3.84%	4.67%	5.87%	5.29%
First Lien Term Loan | New First Lien Term Loan | Senior Notes | Subsequent Event
Debt Instrument [Line Items]
Debt instrument, face amount								$ 600,000,000
Second Lien Term Loan | Credit Agreements Amendment | Senior Notes
Debt Instrument [Line Items]
Repayment of debt					$ 122,900,000
Effective rate on term loans at end of period							8.98%
Weighted average interest rate paid on term loans during period		8.98%		9.51%		10.17%
Second Lien Term Loan | Credit Agreements Amendment | Notes Payable
Debt Instrument [Line Items]
Repayment of debt					$ 245,800,000

INDEBTEDNESS - Long Term Debt M

INDEBTEDNESS - Long Term Debt Maturities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
2021	$ 2,944
2022	11,775
2023	11,775
2024	11,775
2025	11,775
Thereafter	1,106,875
Total	$ 1,156,919	$ 1,161,531

INDEBTEDNESS - Estimated Fair V

INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2021	Sep. 30, 2021	Sep. 30, 2020
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Principal prepayment		$ (8,832)	$ (6,937)
Second lien notes
Debt Instrument [Line Items]
Total debt instruments	$ 0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Second lien notes fair value, beginning of period	266,438	266,438
Principal prepayment	(245,781)
Change in fair value	(20,657)
Second lien notes fair value, end of period	$ 0
Senior Notes
Debt Instrument [Line Items]
Total debt instruments		1,129,598
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Second lien notes fair value, end of period		1,129,598
Senior Notes | First lien term loan
Debt Instrument [Line Items]
Total debt instruments		1,129,598
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Second lien notes fair value, end of period		1,129,598
Senior Notes | Second lien notes
Debt Instrument [Line Items]
Total debt instruments		0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Second lien notes fair value, end of period		0
Senior Notes | Markets for Identical Item (Level 1)
Debt Instrument [Line Items]
Total debt instruments		0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Second lien notes fair value, end of period		0
Senior Notes | Markets for Identical Item (Level 1) | First lien term loan
Debt Instrument [Line Items]
Total debt instruments		0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Second lien notes fair value, end of period		0
Senior Notes | Markets for Identical Item (Level 1) | Second lien notes
Debt Instrument [Line Items]
Total debt instruments		0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Second lien notes fair value, end of period		0
Senior Notes | Significant Other Observable Inputs (Level 2)
Debt Instrument [Line Items]
Total debt instruments		1,156,919
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Second lien notes fair value, end of period		1,156,919
Senior Notes | Significant Other Observable Inputs (Level 2) | First lien term loan
Debt Instrument [Line Items]
Total debt instruments		1,156,919
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Second lien notes fair value, end of period		1,156,919
Senior Notes | Significant Other Observable Inputs (Level 2) | Second lien notes
Debt Instrument [Line Items]
Total debt instruments		0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Second lien notes fair value, end of period		0
Senior Notes | Significant Unobservable Inputs (Level 3)
Debt Instrument [Line Items]
Total debt instruments		0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Second lien notes fair value, end of period		0
Senior Notes | Significant Unobservable Inputs (Level 3) | First lien term loan
Debt Instrument [Line Items]
Total debt instruments		0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Second lien notes fair value, end of period		0
Senior Notes | Significant Unobservable Inputs (Level 3) | Second lien notes
Debt Instrument [Line Items]
Total debt instruments		0
Debt Instrument, Changes In Long-Term Debt [Roll Forward]
Second lien notes fair value, end of period		$ 0

DERIVATIVE INSTRUMENTS - Additi

DERIVATIVE INSTRUMENTS - Additional Information (Details) - Interest Rate Swap - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	May 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	May 30, 2020	Nov. 30, 2019	Aug. 31, 2019
Derivative [Line Items]
Notional amount of derivative								$ 925,000
Interest expense
Derivative [Line Items]
Accumulated comprehensive loss reclassified	$ 3,700	$ 2,903	$ 4,152	$ 11,298	$ 8,604
Not Designated as Hedging Instrument
Derivative [Line Items]
Notional amount of derivative								13,900
Credit Agreements, Entered Into 2019 | Designated as Hedging Instrument | Senior Notes | Second Lien Term Loan
Derivative [Line Items]
Notional amount of derivative						$ 400,000	$ 400,000
Cash Flow Hedging | Designated as Hedging Instrument
Derivative [Line Items]
Notional amount of derivative								$ 911,100

DERIVATIVE INSTRUMENTS - Balanc

DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Fair value - Derivatives in liability position
Total derivatives	$ 0	$ 11,342
Designated as Hedging Instrument | Accrued expenses and other current liabilities | Interest Rate Swap
Fair value - Derivatives in liability position
Interest rate swaps	0	11,172
Not Designated as Hedging Instrument | Accrued expenses and other current liabilities | Interest Rate Swap
Fair value - Derivatives in liability position
Interest rate swaps	$ 0	$ 170

DERIVATIVE INSTRUMENTS - Pre-ta

DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	May 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Derivative [Line Items]
Pre-tax gains (losses) on interest rate derivatives recognized		$ 2,892	$ 4,022	$ 11,172	$ (8,034)
Total gain (loss) on derivatives		(2,903)	(4,193)	(11,300)	(12,382)
Interest Rate Swap
Derivative [Line Items]
Pre-tax gains (losses) on interest rate derivatives recognized		2,892	4,022	11,172	(11,780)
Interest rate swaps that discontinued hedge accounting		0	0	0	3,746
Interest Rate Swap | Interest expense
Derivative [Line Items]
Gain (loss) location of derivative instruments	$ (3,700)	(2,903)	(4,152)	(11,298)	(8,604)
Gain (loss) location of derivative instruments not designated		0	(41)	(2)	(32)
Gain (loss) location of discontinued derivative instruments		$ 0	$ 0	$ 0	$ (3,746)

STOCK-BASED INCENTIVE COMPENS_2

STOCK-BASED INCENTIVE COMPENSATION (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	May 03, 2018
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of shares authorized (in shares)					9,101,734
HC I Incentive Units
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation expense	$ 2.5	$ 1.2	$ 6.2	$ 2.6

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2021shares	Sep. 30, 2021shares	Dec. 31, 2020shares
Common Stock | 2017 Warrants
Class of Warrant or Right [Line Items]
Number of shares purchasable through warrants (in shares)	1,400,000	1,400,000	1,400,000
Common Stock | 2015 Warrants
Class of Warrant or Right [Line Items]
Number of shares purchasable through warrants (in shares)	900,000	900,000	900,000
HC Group Holdings I, LLC
Class of Warrant or Right [Line Items]
Percentage of common stock		0.211
Common Stock | Public Offering | HC Group Holdings I, LLC
Class of Warrant or Right [Line Items]
Additional shares issued (in shares)	29,900,000	76,400,000

RELATED-PARTY TRANSACTIONS (Det

RELATED-PARTY TRANSACTIONS (Details) - Joint Venture - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Related Party Transaction [Line Items]
Management fee income	$ 0.9	$ 0.8	$ 2.6	$ 2.1
Due to joint ventures	$ 2.9		$ 2.9		$ 2.4

SUBSEQUENT EVENTS - Narrative (

SUBSEQUENT EVENTS - Narrative (Details) - USD ($)	Oct. 01, 2021	Oct. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Original issue discount			$ 8,731,000	$ 13,355,000
Senior Notes | First lien term loan
Subsequent Event [Line Items]
Original issue discount			$ 8,731,000	$ 7,253,000
Subsequent Event
Subsequent Event [Line Items]
Repayments of long-term debt		$ 69,900,000
Subsequent Event | Senior Notes
Subsequent Event [Line Items]
Third party fees		9,400,000
Original issue discount		1,500,000
Subsequent Event | Senior Notes | First lien term loan
Subsequent Event [Line Items]
Debt instrument, face amount		1,157,000,000
Subsequent Event | Senior Notes | First lien term loan | Interest Rate Cap | Designated as Hedging Instrument
Subsequent Event [Line Items]
Notional amount of derivative		$ 300,000,000
Derivative, term of contract		5 years
Subsequent Event | Senior Notes | New First Lien Term Loan | First Lien Term Loan
Subsequent Event [Line Items]
Debt instrument, face amount		$ 600,000,000
Subsequent Event | Senior Notes | New Senior Unsecured Notes
Subsequent Event [Line Items]
Debt instrument, face amount		$ 500,000,000
Subsequent Event | Infinity Infusion Nursing, LLC
Subsequent Event [Line Items]
Business combination purchase price	$ 50,000,000